Type 2 Diabetes Medication Improves Liver Health in Mice Fed High Fat Diet

SGLT2 inhibition leads to a restoration of hepatic and circulating metabolites involved in the folate cycle and pyrimidine biosynthesis
Type 2 Diabetes:- SGLT2 inhibition leads to a restoration of hepatic and circulating metabolites involved in the folate cycle and pyrimidine biosynthesis [Pixabay]
Type 2 Diabetes:- SGLT2 inhibition leads to a restoration of hepatic and circulating metabolites involved in the folate cycle and pyrimidine biosynthesis [Pixabay]
Updated on

Type 2 Diabetes:- SGLT2 inhibition leads to a restoration of hepatic and circulating metabolites involved in the folate cycle and pyrimidine biosynthesis

Authors: Ileana Mendez Espinoza, Elijah N. D. Choos, Carolyn M. Ecelbarger, Blythe D. Shepard

From the authors: “Here, we report that empagliflozin reduces hepatic steatosis that is associated with restoring metabolic intermediates in the folate and pyrimidine biosynthesis pathways. These changes may lead to new approaches to treat nonalcoholic fatty liver disease.”

This study is highlighted as one of September’s “best of the best” as part of the American Physiological Society's APSselect program. Newswise/SP

Subscribe to our channels on YouTube and WhatsApp

Download our app on Play Store

logo
NewsGram - Your Most Trusted Place for News with Substance
www.newsgram.com